In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CRISPR raises $29mm in Series B financing; adds $38mm

Executive Summary

In a Series B financing led by new investors SR One and Celgene Corp., CRISPR Therapeutics (using the CRISPR-Cas9 gene editing tools to create new drug candidates) raised $29mm. Additional first-time backers New Enterprise Associates and Abingworth joined returning shareholder Versant Ventures. Simultaneously, the same investors added $35mm to the Series A round CRISPR initiated a year ago, bringing that total to $60mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies